(GILD) Gilead Sciences - Ratings and Ratios
Antivirals, Oncology, Hepatitis, Covid, Hiv
GILD EPS (Earnings per Share)
GILD Revenue
Description: GILD Gilead Sciences September 25, 2025
Gilead Sciences (NASDAQ:GILD) is a U.S.–based biopharmaceutical firm that discovers, develops, and commercializes medicines targeting unmet medical needs across the United States, Europe, and other global markets. Its core therapeutic areas include HIV/AIDS (e.g., Biktarvy, Genvoya, Truvada), viral hepatitis (e.g., Epclusa, Harvoni), COVID-19 (Veklury), oncology (Yescarta, Tecartus, Trodelvy), pulmonary arterial hypertension (Letairis), and invasive fungal infections (AmBisome). The company also maintains an extensive network of collaborations with partners such as Merck, Galapagos, Janssen, and Arcus to broaden its pipeline.
In fiscal 2023 Gilead reported revenue of approximately $27.3 billion, driven primarily by its HIV franchise (+7% YoY) and a modest rebound in hepatitis sales, while Veklury contributed less than 2% of total revenue as COVID-19 demand waned. R&D expenditure was $5.8 billion (≈21% of revenue), reflecting heavy investment in next-generation oncology and cell-therapy assets. The balance sheet remained strong with $13 billion in cash and marketable securities, providing flexibility for potential acquisitions or accelerated development of late-stage candidates. These figures assume the company’s publicly filed 10-K data are accurate and do not account for any post-year-end adjustments.
Key drivers of Gilead’s outlook include: (1) the durability of its HIV product line amid growing competition from generic entrants and pricing pressure in major markets; (2) the success of its oncology pipeline-particularly the upcoming Phase III readout for Trodelvy in triple-negative breast cancer, which could unlock a multi-billion-dollar revenue stream; and (3) broader sector dynamics such as the biotech industry’s elevated cost-of-capital environment and the FDA’s evolving accelerated-approval pathways, which together shape the risk-adjusted return profile of new therapeutics.
For analysts looking to deepen their valuation framework, a quick review of Gilead’s metrics on ValueRay can help surface comparable peer multiples and scenario-based cash-flow models without committing to a full research report.
GILD Stock Overview
| Market Cap in USD | 152,766m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1992-01-22 |
GILD Stock Ratings
| Growth Rating | 84.4% |
| Fundamental | 81.2% |
| Dividend Rating | 61.6% |
| Return 12m vs S&P 500 | 9.63% |
| Analyst Rating | 4.13 of 5 |
GILD Dividends
| Dividend Yield 12m | 2.64% |
| Yield on Cost 5y | 6.47% |
| Annual Growth 5y | 3.16% |
| Payout Consistency | 100.0% |
| Payout Ratio | 38.3% |
GILD Growth Ratios
| Growth Correlation 3m | 50.5% |
| Growth Correlation 12m | 87.6% |
| Growth Correlation 5y | 86.9% |
| CAGR 5y | 17.54% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.66 |
| CAGR/Mean DD 3y (Pain Ratio) | 2.05 |
| Sharpe Ratio 12m | 1.45 |
| Alpha | 26.92 |
| Beta | 0.334 |
| Volatility | 24.17% |
| Current Volume | 9039.2k |
| Average Volume 20d | 6311.1k |
| Stop Loss | 115.2 (-3.1%) |
| Signal | 1.00 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (8.11b TTM) > 0 and > 6% of Revenue (6% = 1.75b TTM) |
| FCFTA 0.16 (>2.0%) and ΔFCFTA -1.03pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 22.48% (prev 10.80%; Δ 11.68pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.17 (>3.0%) and CFO 9.67b > Net Income 8.11b (YES >=105%, WARN >=100%) |
| Net Debt (-9.35b) to EBITDA (12.73b) ratio: -0.73 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.53 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.25b) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 78.71% (prev 76.11%; Δ 2.60pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 51.45% (prev 51.90%; Δ -0.45pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 6.88 (EBITDA TTM 12.73b / Interest Expense TTM 1.02b) >= 6 (WARN >= 3) |
Altman Z'' 2.54
| (A) 0.11 = (Total Current Assets 18.84b - Total Current Liabilities 12.30b) / Total Assets 58.53b |
| (B) 0.20 = Retained Earnings (Balance) 11.50b / Total Assets 58.53b |
| (C) 0.12 = EBIT TTM 7.01b / Avg Total Assets 56.53b |
| (D) 0.31 = Book Value of Equity 11.63b / Total Liabilities 37.08b |
| Total Rating: 2.54 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 81.16
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 5.60% = 2.80 |
| 3. FCF Margin 32.73% = 7.50 |
| 4. Debt/Equity 1.24 = 1.77 |
| 5. Debt/Ebitda -0.73 = 2.50 |
| 6. ROIC - WACC (= 6.79)% = 8.48 |
| 7. RoE 40.74% = 2.50 |
| 8. Rev. Trend 43.92% = 3.29 |
| 9. EPS Trend 16.34% = 0.82 |
What is the price of GILD shares?
Over the past week, the price has changed by -0.79%, over one month by +1.76%, over three months by +8.51% and over the past year by +25.01%.
Is Gilead Sciences a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GILD is around 129.68 USD . This means that GILD is currently overvalued and has a potential downside of 9.12%.
Is GILD a buy, sell or hold?
- Strong Buy: 15
- Buy: 4
- Hold: 11
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the GILD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 129.5 | 9% |
| Analysts Target Price | 129.5 | 9% |
| ValueRay Target Price | 141.7 | 19.3% |
GILD Fundamental Data Overview November 06, 2025
P/E Trailing = 18.894
P/E Forward = 12.7551
P/S = 5.252
P/B = 6.9725
P/EG = 0.208
Beta = 0.334
Revenue TTM = 29.09b USD
EBIT TTM = 7.01b USD
EBITDA TTM = 12.73b USD
Long Term Debt = 24.90b USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.81b USD (from shortTermDebt, last fiscal year)
Debt = 26.71b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -9.35b USD (from netDebt column, last quarter)
Enterprise Value = 170.12b USD (152.77b + Debt 26.71b - CCE 9.35b)
Interest Coverage Ratio = 6.88 (Ebit TTM 7.01b / Interest Expense TTM 1.02b)
FCF Yield = 5.60% (FCF TTM 9.52b / Enterprise Value 170.12b)
FCF Margin = 32.73% (FCF TTM 9.52b / Revenue TTM 29.09b)
Net Margin = 27.88% (Net Income TTM 8.11b / Revenue TTM 29.09b)
Gross Margin = 78.71% ((Revenue TTM 29.09b - Cost of Revenue TTM 6.19b) / Revenue TTM)
Gross Margin QoQ = 79.80% (prev 78.80%)
Tobins Q-Ratio = 2.91 (Enterprise Value 170.12b / Total Assets 58.53b)
Interest Expense / Debt = 0.96% (Interest Expense 256.0m / Debt 26.71b)
Taxrate = 16.18% (589.0m / 3.64b)
NOPAT = 5.87b (EBIT 7.01b * (1 - 16.18%))
Current Ratio = 1.53 (Total Current Assets 18.84b / Total Current Liabilities 12.30b)
Debt / Equity = 1.24 (Debt 26.71b / totalStockholderEquity, last quarter 21.46b)
Debt / EBITDA = -0.73 (Net Debt -9.35b / EBITDA 12.73b)
Debt / FCF = -0.98 (Net Debt -9.35b / FCF TTM 9.52b)
Total Stockholder Equity = 19.91b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.86% (Net Income 8.11b / Total Assets 58.53b)
RoE = 40.74% (Net Income TTM 8.11b / Total Stockholder Equity 19.91b)
RoCE = 15.64% (EBIT 7.01b / Capital Employed (Equity 19.91b + L.T.Debt 24.90b))
RoIC = 13.08% (NOPAT 5.87b / Invested Capital 44.93b)
WACC = 6.29% (E(152.77b)/V(179.48b) * Re(7.25%) + D(26.71b)/V(179.48b) * Rd(0.96%) * (1-Tc(0.16)))
Discount Rate = 7.25% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.08%
[DCF Debug] Terminal Value 77.65% ; FCFE base≈9.48b ; Y1≈9.09b ; Y5≈8.86b
Fair Price DCF = 127.3 (DCF Value 158.08b / Shares Outstanding 1.24b; 5y FCF grow -5.51% → 3.0% )
EPS Correlation: 16.34 | EPS CAGR: 15.30% | SUE: 1.63 | # QB: 1
Revenue Correlation: 43.92 | Revenue CAGR: 1.84% | SUE: 1.15 | # QB: 1
Additional Sources for GILD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle